
263: Biogen's messy board, Laronde's data problem, & the downside of a boom
The Readout Loud
00:00
The Future of Moderna Pharmaceuticals
The company was valued at multiple billion dollars, according to an internal slide deck. Now they're sort of like, you know, a company in search of a mission to apply that funding. It almost kind of reminds me of what's happening with EQRX where they've got all this money, but their original goal is kind of erased or gone.
Transcript
Play full episode